Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7410 participants.
Also called NCT02915198
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 7,410 participants
- Registry
-
NCT02915198
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT02915198. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-03 (actual); primary completion 2029-09-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- Acronym
- VA-IMPACT
- Condition
- Prediabetic State
- Condition
- Atherosclerosis
- Condition
- Metformin
- Intervention (Drug)
- Metformin XR
- Intervention (Drug)
- Placebo
- Lead sponsor
- VA Office of Research and Development
Record details
- Record id
cardio:ct-nct02915198- Content hash
eb744d0bc295b9a6a57f0b3f25cadf73d9ee78435cda961a6f0309860aa62936